MBXBF (Microbix Biosystems) LT-Debt-to-Total-Asset : 0.16 (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Microbix Biosystems LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Microbix Biosystems's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.16.

Microbix Biosystems's long-term debt to total assets ratio declined from Dec. 2023 (0.18) to Dec. 2024 (0.16). It may suggest that Microbix Biosystems is progressively becoming less dependent on debt to grow their business.

Microbix Biosystems LT-Debt-to-Total-Asset Historical Data

The historical data trend for Microbix Biosystems's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microbix Biosystems LT-Debt-to-Total-Asset Chart

Microbix Biosystems Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.18

0.17

0.18

0.16

Microbix Biosystems Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.18	0.17	0.16	0.16	0.16

Microbix Biosystems LT-Debt-to-Total-Asset Calculation

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (A: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2024 )	/	Total Assets (A: Sep. 2024 )
	=	4.544	/	28.124
	=	0.16

Microbix Biosystems's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	4.366	/	27.584
	=	0.16

Microbix Biosystems (OTCPK:MBXBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Microbix Biosystems LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Microbix Biosystems's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Microbix Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Microbix Biosystems Inc (OTCPK:MBXBF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MBX:Canada

Address

265 Watline Avenue, Mississauga, ON, CAN, L4Z 1P3

Website

https://www.microbix.com

Microbix Biosystems Inc develops biological products and technologies. There are two operating segments: The development, manufacturing, and sale of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and; Development and commercialization of novel and proprietary products or technologies such as Kinlytic. Geographically, it derives a majority of revenue from North America and also operates in Europe and other foreign countries.